"Leica" Bond Ready-to-Use Primary Antibody Cytokeratin 20 (Ks20.8) (Non-Sterile)
Taiwan·Risk Class 1·MD·LEICA BIOSYSTEMS NEWCASTLE LTD.·Registered Mar 29, 2019 – Mar 29, 2024Expired- Analysis ID
- 698d4fe8a3b1eaffe9ff180936557fc9
- License Form
- Ministry of Health Medical Device Import No. 020252
- Customs Code
- DHA09402025202
- Manufacturer
- LEICA BIOSYSTEMS NEWCASTLE LTD.
- Manufacturer Country
- United Kingdom
- Authorized Representative
- BECKMAN COULTER TAIWAN INC., TAIWAN BRANCH (U.S.A.)
- Intended Use
- Limited to the first level identification range of immunopathological histochemical reagents and kits (B.1860) of the Measures for the Administration of Medical Devices.
- Product Type (Level 1)
- B Hematology and pathology devices
- Product Type (Level 2)
- B1860 Immunopathological histochemical reagents and kits
- Import Information
- Imported from abroad
- Registration Date
- Mar 29, 2019
- Expiry Date
- Mar 29, 2024
Access comprehensive regulatory information for "Leica" Bond Ready-to-Use Primary Antibody Cytokeratin 20 (Ks20.8) (Non-Sterile) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number 698d4fe8a3b1eaffe9ff180936557fc9 and manufactured by LEICA BIOSYSTEMS NEWCASTLE LTD.. The authorized representative in Taiwan is BECKMAN COULTER TAIWAN INC., TAIWAN BRANCH (U.S.A.).
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.